MLV Capital rated Medicinova, Inc. (NASDAQ: MNOV) to Buy with price target $6
MLV Capital rated Medicinova,
Inc. (NASDAQ: MNOV) to Buy with price target $6.
, incorporated in September 2000, is a biopharmaceutical company focused on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical need with a specific focus on the United States market. Through strategic alliances primarily with Japanese pharmaceutical companies, the Company is developing a portfolio of clinical and preclinical product candidates. Medicinova has acquired licenses to eight compounds for the development of 10 product candidates. Its development pipeline includes eight programs which have been in clinical development for the treatment of asthma, acute exacerbations of asthma, multiple sclerosis, or MS, interstitial cystitis (IC), solid tumor cancers, Generalized Anxiety Disorder/insomnia, preterm labor and urinary incontinence. The Company is focused on the development of two prioritized assets in its development pipeline: MN-221 for the treatment of status asthmaticus, and MN-166 for the treatment of MS.
is a boutique investment bank and institutional broker-dealer focused on providing independent financial advice and unique capital markets expertise to corporate and institutional clients in capital intensive industries such as metals and mining, life sciences, energy and real estate. With a focus on raising money efficiently for clients, MLV has rapidly become a leader in the At-the-Market(ATM) transaction market.